RESUMO
Serum angiotensin converting enzyme (SACE) was estimated in 18 cases of sarcoidosis, 15 patients suffering from pulmonary tuberculosis and in 12 normal healthy individuals. SACE was elevated in the patients suffering from sarcoidosis. (33.2 +/- 12.9). SACE values for the pulmonary tuberculosis patients were 18.8 +/- 7.9 and those for the normal healthy individuals were 17.1 +/- 4.7. Compared to pulmonary tuberculosis and normal healthy individuals, the SACE levels were significantly elevated (P < 0.01) in sarcoidosis patients.
Assuntos
Humanos , Pneumopatias/sangue , Peptidil Dipeptidase A/sangue , Sarcoidose/sangue , Espectrofotometria , Tuberculose Resistente a Múltiplos Medicamentos/sangue , Tuberculose Pulmonar/sangueRESUMO
HLA typing was performed on 18 patients suffering from sarcoidosis and 30 patients suffering from diffuse interstitial pulmonary fibrosis. One hundred normal healthy people ethnically matched served as the controls. On statistical analysis, the corrected 'p' value of all the HLA antigens for both the patient groups was non significant. The results therefore suggest that there is no particular HLA antigen associated with sarcoidosis and diffuse interstitial pulmonary fibrosis.
Assuntos
Estudos de Casos e Controles , Etnicidade , Antígenos HLA/análise , Antígenos HLA-A/análise , Antígenos HLA-B/análise , Antígenos HLA-C/análise , Antígenos HLA-DR/análise , Humanos , Pneumopatias/imunologia , Fibrose Pulmonar/imunologia , Sarcoidose/imunologiaRESUMO
Twenty-five resident doctors were given 1 ml (20 micrograms) of recombinant hepatitis B vaccine intramuscularly in the deltoid region at 0, 1 and 6 months. Seroconversion rates at 1, 2, 3, 7 and 8 months were 8%, 48%, 64%, 96% and 100% respectively. Acceptability of the vaccine was 100%. The recombinant hepatitis B vaccine is safe and efficacious, with seroconversion rates comparable to the plasma derived vaccine, and has negligible side effects.